AB0703 The need for anti-osteoporotic therapy in patients with systemic sclerosis

Abstract

ObjectivesTo determine the need for anti-osteoporotic therapy in postmenopausal women and men over 50 years of age with systemic sclerosis (SSc).MethodsThe study included 150 patients with SSc who met the ACR/EULAR 2013 criteria: 124 (82,7%) postmenopausal women and 26 (17.3%) men over 50 years of age. Median age was 59,0 [54,0; 64,0] years. The duration of the disease was 8,0 [5,0; 14,5] years. A history of fragility fractures was collected. FRAX was calculated in patients without prior fractures to identify patients at high risk of low-energy fractures. Dual-energy X-ray densitometry (DXA) was performed in persons at moderate risk of fractures, and 10-year probability of major osteoporotic fractures was recalculated with the inclusion of a hip neck T-score. DXA was also performed on all patients from the low-risk group who had 2 or more risk factors of OP.Results36 (24%) patients had a history of fragility fractures: 21 (16.9%) women and 6 (4.3%) men - vertebrae fracture, 8 (6.5%) women - peripheral fractures, 1 (3.8%) man – hip fracture.The calculation of the 10-year probability of fractures by FRAX showed that 21 (16,9%) women had a high risk, and another 60 women and 3 men had moderate risk of fractures. After the FRAX recalculation with the inclusion of the femoral neck T-score, only 26 (21,0%) women moved from the moderate-risk group to the high-risk group. All men and 48 women had a low risk of osteoporotic fractures according to FRAX, among them 12 (8,0%) people (4 men and 8 women) had osteoporosis by DXA.Thus, among SSc patients 84 (67.7%) women and 11 (42,3%) men needed anti-osteoporotic treatment.ConclusionAs a result of a comprehensive assessment of the risk of fractures and OP, it was found that 63.3% of patients with SSc needed anti-osteoporotic treatment.Disclosure of InterestsNone declared